A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
Clinical trial NCT04385563 · UNKNOWN
Trial details
- NCT number
- NCT04385563
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-11
- Primary completion
- 2021-02-01
- Enrollment
- 338
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.